参考文献：
Angwin, P., Berger, P., Zarcone, V., Brodie, H.K.H., and Barchas, J. %Hydroxytryptophan: A method for monitoring human plasma content during clinical administration. Neuro[1]chemical Research, 1, 649 (1976).
Bergstrom, R.F., Kay, D.R., Harkcom, T.M., and Wagner, J.G. Penicillamine kinetics in normal subject. Clinical Pharmacology & Therapeutics, 30, 404 (I 981).
Bianchine, J.R., and Shaw, G.M. Clinical pharmacokinetics of levodopa in Parkinson’s disease. Clinical Pharmacokinetics, 1, 313 (1976).
Bodemar, G., Norlander, B., Fransson, L., and Walan, A. The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorp[1]tion of cimetidine-Studies in patients with peptic ulcer disease. British Journal of Clinical Pharmacology, 7, 23 (1979).
Chadwick, D., Hallstett, M., Harris, R., Jenner, P., Reynolds, E.H., and Marsden, CD. Clinical, biochemical and physiological features distinguishing myoclonus responsive to 5hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain, 100, 455 (1977).
Cotler, S., Holazo, A., Boxenbaum, H.G., and Kaplan, S.A. Influence of the route of admin[1]istration on physiological availability of levodopa in dogs. Journal of Pharmaceutical Sciences, 65, 822 (1976).
Guilleminault, C., Tharp, B.R., and Consin, C. HVA and S-HIAA CSF measurement and 5-HTP trials in some patients with involuntary movements. Journal of the Neurological Sciences, 18, 435 (1973).
Handwerger, S., Plonk, J.W., Lebovitz, H.E., Bivens, C.H., and Feldman, J.M. Failure of 5-hydroxytryptophan to stimulate prolactin and growth hormone secretion in man. Hormone and Metabolic Research, 7, 214 (1975).
Horita, A., and Hamilton, A.E. Potentiation of central actions of 5-hydroxytryptophan in rabbits by D-L-o-hydrazino-b-methyldopa. Journal of Pharmacy and Pharmacology, 22,389 (1970).
